<p>随着 2026 年的到来，亚洲市场呈现出不同的动能，中国的制造业部门显示出复苏的迹象，而韩国的出口达到了创纪录的高点。在这个动态的环境中，识别高增长的科技股票需要寻找能够利用区域经济趋势和技术进步来推动创新并占据市场份额的公司。</p>
<h3>亚洲十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>巨人网络集团</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中际旭创</td>
<td>36.62%</td>
<td>38.27%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>福斯泰克</td>
<td>37.25%</td>
<td>52.10%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金回路电子</td>
<td>31.06%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>生益电子</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>知商</td>
<td>35.50%</td>
<td>33.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>生益科技有限公司</td>
<td>21.94%</td>
<td>32.84%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLL 有限公司</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科技发展</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科济药业-B</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们亚洲高增长科技和人工智能股票筛选器的 186 只股票的完整列表。</p>
<p>让我们从我们的专业筛选器中发现一些宝藏。</p>
<h2>医渡科技 (SEHK:2158)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 医渡科技是一家投资控股公司，提供利用大数据和人工智能技术的医疗解决方案，业务覆盖中国等多个国家，市值为 60.3 亿港元。</p>
<p><strong>运营：</strong> 医渡科技通过三个主要业务部门产生收入：生命科学解决方案（2.4075 亿人民币）、大数据平台和解决方案（3.654 亿人民币）以及健康管理平台和解决方案（1.3749 亿人民币）。该公司利用大数据和人工智能技术在中国、文莱和新加坡等多个国家提供医疗解决方案。</p>
<p>医渡科技作为亚洲高增长科技领域的一员，展现出韧性和显著增长潜力。报告显示，销售额同比增长至 3.5811 亿人民币，较上年的 3.2945 亿人民币有所增加，净亏损大幅减少至 1460 万人民币，较上年的 4345 万人民币有所改善，显示出良好的财务复苏趋势。尽管目前尚未盈利，医渡的收入预计将以 17.7% 的年增长率增长，超过香港市场平均 8.4% 的增速。此外，盈利预计将以 94.18% 的年增长率激增，使医渡在未来三年内有望实现盈利，尽管目前在竞争激烈的医疗服务领域表现平平，预测的股本回报率仅为 1.9%。</p>
<ul>
<li>在这里深入了解医渡科技的具体情况，查看我们的详细健康报告。</li>
<li>通过查看我们的历史业绩报告，获取医渡科技的历史表现洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c787a8e8-cf73-4138-a828-dd7fdee4d0e9/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c787a8e8-cf73-4138-a828-dd7fdee4d0e9/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 1 月的 SEHK:2158 收入和支出明细</p>
<h2>甘李药业 (SHSE:603087)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 甘李药业是一家生物制药公司，专注于胰岛素类似物活性药物成分（API）和注射剂的研究、开发、生产和销售，市值约为 425.5 亿人民币。</p>
<p><strong>运营：</strong> 甘李药业的收入主要来自胰岛素及相关产品的开发、生产和销售，金额为 38.5 亿人民币。该公司的运营专注于中国的生物制药领域。</p>
<p>在强劲的亚洲科技环境中，甘李药业在创新糖尿病治疗方面取得了显著进展。公司最近宣布与 Lupin 签署许可协议，推出 Bofanglutide，可能成为首个每两周一次的 GLP-1 受体激动剂，有望改变肥胖和糖尿病管理。这一消息紧随其胰岛素甘精胰岛素获得 EMA 的生物类似药认证，突显了甘李药业在慢性病护理领域扩展全球足迹的承诺。甘李药业的收入同比增长 35.8%，盈利增长 61.3%，不仅超越了区域增长率，还巩固了其在未来医疗解决方案中的角色。</p>
<ul>
<li>在这里深入了解甘李药业的完整分析健康报告。</li>
<li>查看我们的历史业绩报告，以获取甘李药业的过去表现洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 1 月的 SHSE:603087 收入和支出明细</p>
<h2>迅博科技 (TWSE:2345)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 迅博科技股份有限公司从事计算机网络系统及无线局域网硬件和软件产品的开发、制造和销售，业务覆盖台湾、美国、亚太地区、欧洲及其他国际市场，市值为 6734.8 亿新台币。</p>
<p><strong>运营：</strong> 迅博科技的主要收入来源于其计算机网络部门，收入为 2152.7 亿新台币。该公司在台湾、美国和欧洲等多个地区运营。</p>
<p>Accton Technology 最近与 Edgecore Networks、1Finity 和 Liqid 建立的战略联盟，旨在开发尖端的数据中心解决方案，突显了其在亚洲科技领域的创新优势。此次合作旨在增强长距离光子网络连接，这对现代数据中心的高传输速率和低延迟至关重要。在财务方面，Accton 的第三季度收入从去年同期的 281.9 亿新台币飙升至 729.5 亿新台币，净收入则增长至 78.3 亿新台币，增长了三倍。这些数据反映出年化收入增长率为 24.1%，盈利增长率为 24.9%，使 Accton 在高需求科技领域的未来扩展中处于良好位置。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Accton Technology 的动态。</li>
<li>了解 Accton Technology 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a35f34df-42b2-4cae-940c-cc2a6dd214f4/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a35f34df-42b2-4cae-940c-cc2a6dd214f4/chart/revenue-and-expenses-breakdown"/></p>
<p>TWSE:2345 截至 2026 年 1 月的收入和支出明细</p>
<h2>总结</h2>
<ul>
<li>点击浏览其余 183 家亚洲高增长科技和人工智能股票。</li>
<li>拥有这些公司的股份？将您的持股整合到 Simply Wall St 的投资组合中，以获取通知和详细的股票报告。</li>
<li>免费使用 Simply Wall St 的应用程序简化您的投资策略，并受益于对全球各地股票的广泛研究。</li>
</ul>
<h2>对其他选择感兴趣？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过分析师和管理层的乐观展望，为您的投资组合注入强劲增长潜力的公司。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>

科济药业-B

医渡科技

中际旭创

<p>随着 2026 年的开始，亚洲市场展现出不同的动能，中国的制造业正在复苏，而韩国的出口达到了创纪录的高点。关键的高增长科技股票包括巨人网络集团、中际旭创和科济药业-B 等。医渡科技和干李药业因其创新的医疗解决方案和显著的收入增长而备受瞩目。艾克顿科技因其在网络系统和战略联盟方面的进展而受到认可。总体而言，亚洲科技领域正处于增长的有利位置，受到经济趋势和技术进步的推动</p>

<p>As 2026 begins, Asian markets are experiencing varied momentum, with China's manufacturing sector showing signs of recovery and South Korea's exports reaching record highs. In this dynamic environment, identifying high growth tech stocks involves looking for companies that can leverage regional economic trends and technological advancements to drive innovation and capture market share.</p>
<div class="lb-trans"><p>随着 2026 年的到来，亚洲市场呈现出不同的动能，中国的制造业部门显示出复苏的迹象，而韩国的出口达到了创纪录的高点。在这个动态的环境中，识别高增长的科技股票需要寻找能够利用区域经济趋势和技术进步来推动创新并占据市场份额的公司。</p>
</div><h3>Top 10 High Growth Tech Companies In Asia</h3>
<div class="lb-trans"><h3>亚洲十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giant Network Group</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>36.62%</td>
<td>38.27%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>37.25%</td>
<td>52.10%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>31.06%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Knowmerce</td>
<td>35.50%</td>
<td>33.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>21.94%</td>
<td>32.84%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>巨人网络集团</td>
<td>34.73%</td>
<td>40.54%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>中际旭创</td>
<td>36.62%</td>
<td>38.27%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>福斯泰克</td>
<td>37.25%</td>
<td>52.10%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金回路电子</td>
<td>31.06%</td>
<td>37.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>生益电子</td>
<td>24.67%</td>
<td>33.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>知商</td>
<td>35.50%</td>
<td>33.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>生益科技有限公司</td>
<td>21.94%</td>
<td>32.84%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLL 有限公司</td>
<td>21.55%</td>
<td>22.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科技发展</td>
<td>35.68%</td>
<td>75.80%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>科济药业-B</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 186 stocks from our Asian High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们亚洲高增长科技和人工智能股票筛选器的 186 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>让我们从我们的专业筛选器中发现一些宝藏。</p>
</div><h2>Yidu Tech (SEHK:2158)</h2>
<div class="lb-trans"><h2>医渡科技 (SEHK:2158)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Yidu Tech Inc. is an investment holding company that offers healthcare solutions leveraging big data and artificial intelligence technologies in various countries, including China, with a market cap of HK$6.03 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 医渡科技是一家投资控股公司，提供利用大数据和人工智能技术的医疗解决方案，业务覆盖中国等多个国家，市值为 60.3 亿港元。</p>
</div><p><strong>Operations:</strong> Yidu Tech generates revenue through three main segments: Life Sciences Solutions (CN¥240.75 million), Big Data Platform and Solutions (CN¥365.40 million), and Health Management Platform and Solutions (CN¥137.49 million). The company leverages big data and AI technologies to provide healthcare solutions across multiple countries, including China, Brunei, and Singapore.</p>
<div class="lb-trans"><p><strong>运营：</strong> 医渡科技通过三个主要业务部门产生收入：生命科学解决方案（2.4075 亿人民币）、大数据平台和解决方案（3.654 亿人民币）以及健康管理平台和解决方案（1.3749 亿人民币）。该公司利用大数据和人工智能技术在中国、文莱和新加坡等多个国家提供医疗解决方案。</p>
</div><p>Yidu Tech, a player in the high-growth tech sector in Asia, has demonstrated resilience and potential for significant growth. With a reported sales increase to CNY 358.11 million from CNY 329.45 million year-over-year and a substantial reduction in net loss to CNY 14.6 million from CNY 43.45 million, the company shows promising financial recovery trends. Despite current unprofitability, Yidu's revenue is projected to grow at an annual rate of 17.7%, outpacing the Hong Kong market's average of 8.4%. Moreover, earnings are expected to surge by an impressive 94.18% annually, positioning Yidu favorably for future profitability within three years as it navigates through the competitive healthcare services landscape where it currently underperforms with a modest forecasted return on equity of only 1.9%.</p>
<div class="lb-trans"><p>医渡科技作为亚洲高增长科技领域的一员，展现出韧性和显著增长潜力。报告显示，销售额同比增长至 3.5811 亿人民币，较上年的 3.2945 亿人民币有所增加，净亏损大幅减少至 1460 万人民币，较上年的 4345 万人民币有所改善，显示出良好的财务复苏趋势。尽管目前尚未盈利，医渡的收入预计将以 17.7% 的年增长率增长，超过香港市场平均 8.4% 的增速。此外，盈利预计将以 94.18% 的年增长率激增，使医渡在未来三年内有望实现盈利，尽管目前在竞争激烈的医疗服务领域表现平平，预测的股本回报率仅为 1.9%。</p>
</div><ul>
<li>Dive into the specifics of Yidu Tech here with our thorough health report.</li>
<li>Gain insights into Yidu Tech's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解医渡科技的具体情况，查看我们的详细健康报告。</li>
<li>通过查看我们的历史业绩报告，获取医渡科技的历史表现洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c787a8e8-cf73-4138-a828-dd7fdee4d0e9/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/c787a8e8-cf73-4138-a828-dd7fdee4d0e9/chart/revenue-and-expenses-breakdown"/></p>
<p>SEHK:2158 Revenue and Expenses Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月的 SEHK:2158 收入和支出明细</p>
</div><h2>Gan &amp; Lee Pharmaceuticals (SHSE:603087)</h2>
<div class="lb-trans"><h2>甘李药业 (SHSE:603087)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Gan &amp; Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China with a market capitalization of approximately CN¥42.55 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 甘李药业是一家生物制药公司，专注于胰岛素类似物活性药物成分（API）和注射剂的研究、开发、生产和销售，市值约为 425.5 亿人民币。</p>
</div><p><strong>Operations:</strong> Gan &amp; Lee Pharmaceuticals generates revenue primarily from the development, production, and sales of insulin and related products, amounting to CN¥3.85 billion. The company's operations focus on the biopharmaceutical sector within China.</p>
<div class="lb-trans"><p><strong>运营：</strong> 甘李药业的收入主要来自胰岛素及相关产品的开发、生产和销售，金额为 38.5 亿人民币。该公司的运营专注于中国的生物制药领域。</p>
</div><p>Gan &amp; Lee Pharmaceuticals, amidst a robust Asian tech landscape, is making significant strides with its innovative diabetes treatments. The company recently announced a licensing agreement with Lupin for Bofanglutide, potentially the first fortnightly GLP-1 receptor agonist, poised to transform obesity and diabetes management. This follows their insulin glargine's endorsement by the EMA as biosimilar to Lantus®, underscoring Gan &amp; Lee's commitment to expanding its global footprint in chronic disease care. With an impressive 35.8% increase in revenue year-over-year and earnings up by 61.3%, Gan &amp; Lee not only outpaces regional growth rates but also solidifies its role in shaping future healthcare solutions.</p>
<div class="lb-trans"><p>在强劲的亚洲科技环境中，甘李药业在创新糖尿病治疗方面取得了显著进展。公司最近宣布与 Lupin 签署许可协议，推出 Bofanglutide，可能成为首个每两周一次的 GLP-1 受体激动剂，有望改变肥胖和糖尿病管理。这一消息紧随其胰岛素甘精胰岛素获得 EMA 的生物类似药认证，突显了甘李药业在慢性病护理领域扩展全球足迹的承诺。甘李药业的收入同比增长 35.8%，盈利增长 61.3%，不仅超越了区域增长率，还巩固了其在未来医疗解决方案中的角色。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Gan &amp; Lee Pharmaceuticals.</li>
<li>Review our historical performance report to gain insights into Gan &amp; Lee Pharmaceuticals''s past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解甘李药业的完整分析健康报告。</li>
<li>查看我们的历史业绩报告，以获取甘李药业的过去表现洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/revenue-and-expenses-breakdown"/></p>
<p>SHSE:603087 Revenue and Expenses Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月的 SHSE:603087 收入和支出明细</p>
</div><h2>Accton Technology (TWSE:2345)</h2>
<div class="lb-trans"><h2>迅博科技 (TWSE:2345)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Accton Technology Corporation is engaged in the development, manufacturing, and sale of computer network systems and wireless LAN hardware and software products across Taiwan, the United States, the Asian-Pacific region, Europe, and other international markets with a market capitalization of NT$673.48 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 迅博科技股份有限公司从事计算机网络系统及无线局域网硬件和软件产品的开发、制造和销售，业务覆盖台湾、美国、亚太地区、欧洲及其他国际市场，市值为 6734.8 亿新台币。</p>
</div><p><strong>Operations:</strong> The primary revenue stream for Accton Technology comes from its computer network segment, generating NT$215.27 billion. The company operates across multiple regions, including Taiwan, the United States, and Europe.</p>
<div class="lb-trans"><p><strong>运营：</strong> 迅博科技的主要收入来源于其计算机网络部门，收入为 2152.7 亿新台币。该公司在台湾、美国和欧洲等多个地区运营。</p>
</div><p>Accton Technology's recent strategic alliance with Edgecore Networks, 1Finity, and Liqid to develop a cutting-edge datacenter solution underscores its innovative edge in Asia's tech sector. This collaboration aims to enhance long-distance photonic network connectivity, crucial for modern datacenters requiring high transmission rates and low latency. Financially, Accton has shown robust growth with third-quarter revenue soaring to TWD 72.95 billion from TWD 28.19 billion year-over-year, while net income tripled to TWD 7.83 billion. These figures reflect a significant annualized revenue growth of 24.1% and earnings growth of 24.9%, positioning Accton well for future expansions in high-demand tech segments.</p>
<div class="lb-trans"><p>Accton Technology 最近与 Edgecore Networks、1Finity 和 Liqid 建立的战略联盟，旨在开发尖端的数据中心解决方案，突显了其在亚洲科技领域的创新优势。此次合作旨在增强长距离光子网络连接，这对现代数据中心的高传输速率和低延迟至关重要。在财务方面，Accton 的第三季度收入从去年同期的 281.9 亿新台币飙升至 729.5 亿新台币，净收入则增长至 78.3 亿新台币，增长了三倍。这些数据反映出年化收入增长率为 24.1%，盈利增长率为 24.9%，使 Accton 在高需求科技领域的未来扩展中处于良好位置。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Accton Technology.</li>
<li>Learn about Accton Technology's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Accton Technology 的动态。</li>
<li>了解 Accton Technology 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a35f34df-42b2-4cae-940c-cc2a6dd214f4/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/a35f34df-42b2-4cae-940c-cc2a6dd214f4/chart/revenue-and-expenses-breakdown"/></p>
<p>TWSE:2345 Revenue and Expenses Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>TWSE:2345 截至 2026 年 1 月的收入和支出明细</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Click through to start exploring the rest of the 183 Asian High Growth Tech and AI Stocks now.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击浏览其余 183 家亚洲高增长科技和人工智能股票。</li>
<li>拥有这些公司的股份？将您的持股整合到 Simply Wall St 的投资组合中，以获取通知和详细的股票报告。</li>
<li>免费使用 Simply Wall St 的应用程序简化您的投资策略，并受益于对全球各地股票的广泛研究。</li>
</ul>
</div><h2>Curious About Other Options?</h2>
<div class="lb-trans"><h2>对其他选择感兴趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过分析师和管理层的乐观展望，为您的投资组合注入强劲增长潜力的公司。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div>

High Growth Tech Stocks in Asia to Watch January 2026

- 2026 年，亚洲市场动能各异，南韩出口创纪录。
- 中国制造业复苏，技术增长潜力被看好。
- 重点公司包括依度科技和甘李药业，均显示出强劲增长趋势。

2026 年 1 月值得关注的亚洲高增长科技股票